Events /// Investor News /// Investment Case /// Resources
Bayer is committed to providing sustainable solutions that address humanity’s most fundamental needs for essential healthcare and nutritious food. The Bayer Investor Relations Team is dedicated to creating transparency, fostering dialogue, and delivering value to our stakeholders.
Upcoming Events and Highlights
Investor News
Share Price / Index
May 09, 2025
Not intended for U.S. and UK Media
Aflibercept 8 mg to treat macular edema following retinal vein occlusion submitted for approval in Japan
April 25, 2025
CEO Bill Anderson at the Annual Stockholders’ Meeting:
“We’re working at full force to put Bayer back on a profitable growth path”
April 08, 2025
Not intended for U.S. and UK Media
Bayer files for approval of aflibercept 8 mg for treatment of retinal vein occlusion in EU
Discover More
